Abstract: AIM To explore the value of thromboelastography in obstructive sleep apnea hypopnea syndromes (OSAHS) patients with chronic heart failure (CHF). METHODS A total of 60 CHF patients diagnosed by polysomnography and cardiology in our hospital were divided into three groups:a mild group (n=20), a moderate group (n=20) and a severe group (n=20). In addition, 20 healthy subjects were selected as a control group. General data were recorded, including age, height, weight, gender, hypertension, smoking history, drinking history and waist circumference. All patients were monitored by polysomnography and thromboelastogram was performed. Blood samples were monitored to detect the time at which the first blood clot was formed (R value) and the maximum coagulation strength (MA) on thromboelastography. The changes of thromboelastogram in serum samples were studied to evaluate the value and the correlation of thromboelastography in OSAHS patients with CHF. RESULTS AHI increased with increase of body mass index (BMI) in mild, moderate and severe OSAHS patients with CHF (P<0.05). Compared with that in control group, the R of OSAHS patients with CHF was significantly lower (P<0.05). The difference between mild, moderate and severe groups was significant (P<0.05). Compared with the control group, the MA value of patients with CHF was significantly higher than that in the control group (P<0.05). The MA of the moderate group and the mild group was significantly higher than that of the control group (P<0.05, P<0.01). The difference between mild, moderate and severe groups was significant(P<0.05, P<0.01). CONCLUSION In OSAHS patients with CHF, BMI is positively correlated with AHI, R value is negatively correlated with AHI and MA value is positively correlated with AHI. The blood of OSAHS patients with CHF is in hypercoagulable states and the more serious the condition of OSAHS patients is, the more serious the blood hypercoagulability state is. Thromboelastography can be used to evaluate the hemagglutination status of OSAHS patients with CHF and to guide antiplatelet aggregation and anticoagulant therapy in clinical practice.